Investigational drug · Phase 2
NT-101
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Wet Age Related Macular Degeneration, Wet AMD.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "NT-101"
First trial start
2025
Mar 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NT-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Wet Age Related Macular Degeneration
- Wet AMD
Approved drugs for the same conditions: Wet macular degeneration · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "NT-101" as an intervention, largest first.
NexThera Co., Ltd.Industry
NCT07811726 · 66 participants (planned) · Start Jun 11, 2026 · Primary completion Feb 28, 2028
Drug: NT-101 ophthalmic solution; Placebo · For: Wet Age Related Macular Degeneration
Sites: Bonita Springs, Florida; Tulsa, Oklahoma; Erie, Pennsylvania
NeuroTau, Inc.Academic, hospital or other
NCT04253132 · 24 participants (planned) · Start Jan 1, 2021 · Primary completion Dec 31, 2022
Drug: Tolfenamic Acid; Placebos · For: Progressive Supranuclear Palsy
Sites: Las Vegas, Nevada
NexThera Co., Ltd.Industry
NCT06704009 · 20 participants · Start Mar 11, 2025 · Primary completion Dec 15, 2025
Drug: NT-101 Low Dose; NT-101 High Dose · For: Wet Age Related Macular Degeneration; Wet AMD
Sites: Rosedale, Maryland; Durham, North Carolina; Erie, Pennsylvania · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Hypertension and Cognitive Dysfunction in a Pregnant Rat Model of PE; a Role for CD4+ T Cells.
Deer E, Herrock O, Simmons K, et al. · Am J Reprod Immunol 2024
- "Silent" β-thalassemia mutation (promoter nt-101 C > T) with increased hemoglobin A2.
Aslan D · Turk J Pediatr 2016
- Electrical potentials between stent-grafts made from different metals induce negligible corrosion.
Kazimierczak A, Podraza W, Lenart S, et al. · Eur J Vasc Endovasc Surg 2013
- Bovine coronavirus nonstructural protein 1 (p28) is an RNA binding protein that binds terminal genomic cis-replication elements.
Gustin KM, Guan BJ, Dziduszko A, et al. · J Virol 2009
- Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells.
Wai PY, Mi Z, Gao C, et al. · J Biol Chem 2006
- Cellular proteins from human monocytes bind to dengue 4 virus minus-strand 3' untranslated region RNA.
Yocupicio-Monroy RM, Medina F, Reyes-del Valle J, et al. · J Virol 2003
Also in development for Wet Age Related Macular Degeneration
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.